12 Month Price Forecast For GYRE
Distance to GYRE Price Forecasts
GYRE Price Momentum
๐ค Considering Gyre Therapeutics (GYRE)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 16, 2025 3:51 AM UTC
GYRE Analyst Ratings & Price Targets
GYRE has shown a year-to-date change of -1.0% and a 1-year change of -22.1%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for GYRE. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GYRE Analyst Consensus
GYRE Price Target Range
Latest GYRE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GYRE.
Date | Firm | Analyst | Rating | Change | Price Target |
---|
Stocks Similar to Gyre Therapeutics Inc.
The following stocks are similar to Gyre Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Gyre Therapeutics Inc. (GYRE) Financial Data
Gyre Therapeutics Inc. has a market capitalization of $1.03B with a P/E ratio of -8.5x. The company generates $105.03M in trailing twelve-month revenue with a -84.6% profit margin.
Revenue growth is -20.5% quarter-over-quarter, while maintaining an operating margin of +16.6% and return on equity of -85.3%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Gyre Therapeutics Inc. (GYRE) Company Overview
About Gyre Therapeutics Inc.
Develops anti-inflammatory and anti-fibrotic drugs.
The company focuses on developing and commercializing small-molecule drugs that target organ fibrosis, generating revenue primarily through the sale of approved therapies and potential future treatments in its pipeline. Its lead product, ETUARY (Pirfenidone), is already on the market for idiopathic pulmonary fibrosis, while ongoing clinical trials aim to expand its indications and introduce new drugs.
Founded in 2002 and based in San Diego, California, Gyre Therapeutics operates as a subsidiary of GNI USA, Inc. The company has a diverse development pipeline with drugs at various stages targeting conditions such as chronic hepatitis B, liver fibrosis, and pulmonary diseases, which could enhance its market presence and revenue potential.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
593
CEO
Dr. Han Ying Ph.D.
Country
United States
IPO Year
2006
Website
www.gyretx.comGyre Therapeutics Inc. (GYRE) Latest News & Analysis
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
3 months agoGyre Therapeutics completed a pivotal Phase 3 trial in CHB-associated liver fibrosis, with data due in Q1 2025. U.S. Phase 2 trial for MASH is set for 2025. Cash reserves are $15.9M as of Sept 30, 2024.
Completion of the Phase 3 trial positions Gyre for potential product approval and revenue growth, while upcoming launches and cash reserves indicate strong operational stability and investment potential.
Gyre Therapeutics announced the completion of its Phase 3 trial for F351 in Chronic Hepatitis B-associated liver fibrosis. Topline data is expected in Q1 2025.
The completion of the Phase 3 trial for F351 marks a critical milestone for Gyre, potentially influencing stock performance and investor sentiment based on upcoming data results.
Gyre Therapeutics (Nasdaq: GYRE) will present a company overview at the H.C. Wainwright MASH Investor Conference on October 7, 2024, at 2:30 PM ET.
Gyre Therapeutics' presentation at a major investor conference could attract interest and investment, signaling potential growth in the biotechnology sector focused on chronic organ diseases.
Gyre Therapeutics Reports Second Quarter 2024 and Year-To-Date Financial Results and Provides Business Update
6 months agoGyre Therapeutics received NMPA approval for avatrombopag for CLD-associated thrombocytopenia and IND approval for F230 for pulmonary arterial hypertension. Cash totaled $16.1 million as of June 30, 2024.
NMPA approvals for new treatments enhance Gyre's product pipeline, potentially driving revenue growth. Cash reserves indicate operational stability amid ongoing clinical developments.
Gyre Therapeutics (Nasdaq: GYRE) will present a company overview at the Sidoti Virtual Investor Conference on August 15, 2024, at 10:45 a.m. ET, focusing on chronic organ disease treatments.
Gyre Therapeutics' presentation at a key investor conference could signal growth opportunities and attract investor interest, impacting stock performance and market perception.
Gyre Therapeutics received approval from China's NMPA for avatrombopag maleate tablets to treat thrombocytopenia in adults with chronic liver disease undergoing elective procedures.
Gyre's approval for avatrombopag in China opens significant market opportunities, potentially boosting revenue and enhancing investor confidence in the company's growth prospects.
Frequently Asked Questions About GYRE Stock
What is Gyre Therapeutics Inc.'s (GYRE) stock forecast for 2025?
Analyst forecasts for Gyre Therapeutics Inc. (GYRE) are not currently available. The stock is trading at $11.98.
Is GYRE stock a good investment in 2025?
Analyst ratings for GYRE are not currently available. The stock is currently trading at $11.98. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for GYRE stock?
Price predictions from Wall Street analysts for GYRE are not currently available. The stock is trading at $11.98.
What is Gyre Therapeutics Inc.'s business model?
The company focuses on developing and commercializing small-molecule drugs that target organ fibrosis, generating revenue primarily through the sale of approved therapies and potential future treatments in its pipeline. Its lead product, ETUARY (Pirfenidone), is already on the market for idiopathic pulmonary fibrosis, while ongoing clinical trials aim to expand its indications and introduce new drugs.
What is the highest forecasted price for GYRE Gyre Therapeutics Inc.?
Price targets from Wall Street analysts for GYRE are not currently available. The stock is trading at $11.98.
What is the lowest forecasted price for GYRE Gyre Therapeutics Inc.?
Price targets from Wall Street analysts for GYRE are not currently available. The stock is trading at $11.98.
What is the overall GYRE consensus from analysts for Gyre Therapeutics Inc.?
Analyst ratings for GYRE are not currently available. The stock is trading at $11.98.
How accurate are GYRE stock price projections?
Stock price projections, including those for Gyre Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.